RELATED CONTENT
The ITM Group announced that its subsidiary ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next-generation theranostic agent for bone targeted radionuclide therapy and diagnostics in patients suffering from bone metastases. DOTA-Zoledronate specifically targets cancerous bone lesions and, when radiolabeled with therapeutic or diagnostic radioisotopes, has shown high potential for positron emission tomography (PET) imaging and endoradiotherapy.
August 20, 2015 
